GLYXAMBI

boehringer ingelheim (canada) ltd ltee🇨🇦 Health Canada

Approval Id: 27731de8ec99f4b3
Drug Approval Canada Name: GLYXAMBI
Product Name: GLYXAMBI
Status: Cancelled Post Market
Status Date: 2021-12-09
Original Market Date: 2016-12-21
Din: 02459760
Drug Class: Human
Dosage Form: Tablet
Route Of Administration: Oral
Schedule: Prescription
Ahfs: 68:20.05
Atc Original: A10BD19 LINAGLIPTIN AND EMPAGLIFLOZIN
Atc Name: a 10 bd 19
Aig Number: 0258690002
Company Name: boehringer ingelheim (canada) ltd ltee
Company Address: 5180 South Service Road, Burlington, Ontario, Canada, L7L 5H4

LINAGLIPTIN

5 MG

EMPAGLIFLOZIN

25 MG

Authorized

Agency

Health Canada

Country

🇨🇦

Approval Date

Jul 4, 2025

Approval ID

27731de8ec99f4b3

Type

Standard